Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Durvalumab in combination with tremelimumab and chemotherapy for unresectable, locally advanced or metastatic urothelial cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2020	View \| Download
Durvalumab in addition to platinum based chemoradiation therapy for treating non-small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line	Cisplatin (Platinol) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Gemcitabine (Gemzar; gemcitabine hydrochloride)	Biliary tract cancer	Gastrointestinal Cancer	2021	View \| Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Head and neck cancer	Head and Neck Cancer	2019	View \| Download
Durvalumab for previously untreated,hepatocellular carcinoma	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab for limited stage small-cell lung cancer after 1 therapy	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download
Durvalumab for advanced, EGFR/ALK wild-type, high PD-L1 expression, non-small cell lung cancer- first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Durvalumab and enfortumab vedotin with or without tremelimumab for muscle-invasive bladder cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Enfortumab vedotin (ASG-22ME; Padcev) , Tremelimumab (CP-675206; CP-675 206)	Bladder cancer	Urological Cancer	2024	View \| Download
Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download